Association Between BKPyV Serotype I Antibody Level and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.

Abstract

To determine the association between BK polyomavirus (BKPyV) types 1 and 4 capsid antibody and natalizumab-associated progressive multifocal leukoencephalopathy (PML) in patients with multiple sclerosis (MS), serum samples were obtained from 10 natalizumab-associated PML cases and 130 control MS patients treated with natalizumab, and 82 control MS patients never exposed to natalizumab. In a sex- and age-adjusted regression model, BKPyV serotype 1 antibody levels were significantly higher in natalizumab-treated controls (p = 0.009) compared with cases, and were higher in controls never treated with natalizumab compared with cases, but the difference did not reach statistical significance (p = 0.158). There was no association between BKPyV serotype 4 antibody and PML. We hypothesize that a robust immune response to BKPyV may be protective against the development of PML.

• Authors: Francesca Rossi, Luca Prosperini, Nicola De Rossi, Ruggero Capra, Daniela Rivanera, Xiuhong Li, Paola Cinque, Laura Passeri, Carlo Pozzilli, Raphael Viscidi
• Journal: Viral immunology (Viral Immunol) Vol. 30 Issue 8 Pg. 622-626 (10 2017) ISSN: 1557-8976 [Electronic] United States
• PMID: 28836899 (Publication Type: Journal Article)

Chemical References

• Antibodies, Viral
• Natalizumab

Topics

• Adult
• Age Factors
• Antibodies, Viral (blood)
• BK Virus (immunology)
• Female
• Humans
• JC Virus (immunology)
• Leukoencephalopathy, Progressive Multifocal (complications, virology)
• Male
• Middle Aged
• Multiple Sclerosis (complications, drug therapy, virology)
• Natalizumab (adverse effects, therapeutic use)
• Polyomavirus Infections (complications, virology)
• Regression Analysis
• Serogroup
• Sex Factors